OncLive TV

Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

August 3rd 2022

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL

August 3rd 2022

Anita Kumar, MD, discusses treatment options for patients with mantle cell lymphoma who progress on BTK inhibitors.

Dr. Borghaei on the Efficacy of Nivolumab/Ipilimumab in STK11/KEAP1-Mutated NSCLC

August 2nd 2022

Hossein Borghaei, DO, MS, discusses the investigation of nivolumab plus ipilimumab and chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. Ligresti on the Need for Screening in Pancreatic Cancer

August 1st 2022

Rosario Ligresti, MD, discusses the need for screening in pancreatic cancer. 

Dr. Slotky on Evolving Treatment with Stem Cell Transplants in Multiple Myeloma

August 1st 2022

Horton on Addressing the Equity Gap of Genetic Testing in Cancer Care

August 1st 2022

Carrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.

Dr. Morgensztern on Advances With Amivantamab in NSCLC

July 30th 2022

Daniel Morgensztern, MD, discusses ongoing research with amivantamab-vmjw in non–small cell lung cancer.

Dr. Bazhenova on Larotrectinib and Entrectinib in NTRK Fusion–Positive NSCLC

July 30th 2022

Lyudmila A. Bazhenova, MD, discusses NTRK inhibition with larotrectinib and entrectinib in patients with NTRK fusion–positive non–small cell lung cancer.

Dr. Pegram on the Evolving Treatment Landscape in HER2+ Breast Cancer

July 29th 2022

Mark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Dr. McAndrew on Chemotherapy Vs Ovarian Function Suppression in HR+ Breast Cancer

July 29th 2022

Nicholas P. McAndrew, MD, MSCE, discusses the relationship between chemotherapy and ovarian function suppression in hormone receptor–positive, HER2-negative breast cancer.

Dr. Bardia on the Need for Oral SERDs in ESR1-Mutant ER+ Breast Cancer

July 29th 2022

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

Dr. Baas on Immunotherapy in Mesothelioma Subpopulations

July 29th 2022

Paul Baas, MD, PhD, discusses the benefits of immunotherapy in subpopulations of patients with mesothelioma. 

Dr Wagner or the Potential Value of Immunotherapy in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.

Dr Wagner on Molecular Pathways in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses molecular pathways that are becoming relevant in angiosarcoma.

Dr. Wagner on Risk Factors for Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses known risk factors for developing angiosarcoma.

Dr. Wagner on the Standard of Care in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the standard of care for patients with angiosarcoma.

Dr. Wagner on Diagnosing Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the challenge of diagnosing angiosarcoma.

Dr. Wagner on the Value of Cooperative Research Groups in Angiosarcoma

July 29th 2022

Michael J. Wagner, MD, discusses the importance of cooperative research groups in angiocarcinoma.

Dr. Reckamp on Treatment Decisions in MET Exon 14–Mutated NSCLC

July 29th 2022

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.

Dr. Gandara on the Evaluation of Tumor Biomarkers in NSCLC

July 28th 2022

David R. Gandara, MD, discusses the evaluation of tumor biomarkers in non–small cell lung cancer.